In addition to these classic features, the CRC Subtyping Consortium classified four consensus molecular subtypes (CMS) of CRC: CMS1, which are enriched for tumors with MSI, overexpression of DNA damage repair proteins, high immune activation and widespread hypermethylation; CMS2, which have tumors with chromosomal instability and activation of the WNT and MYC signaling pathways; CMS3, with tumors with epithelial and metabolic dysregulation; and CMS4, which have tumors with transforming growth factor-β activation, stromal infiltration and angiogenesis6. Here, MYC is linked to colorectal carcinoma.